| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
In this study, we assessed for the first time the safety and efficacy of a new short-term oral immunotherapy (OIT) for Japanese cedar pollinosis using the Cry j1-galactomannan conjugates, which could include high-dose allergens and could be decreased the risk of anaphylaxis. Participants receiving OIT for about two months from a month before the pollen season showed significant improvements in rhinoconjunctivitis and medication use through the pollen season and furthermore the next pollen season without OIT compared with control group. Importantly, no side effects such as life-threatening were observed in participants receiving OIT.
These results suggest that a new short-term OIT using allergen-galactomannan conjugates may provide a rapid, convenient, effective, and safe immunotherapy regimen for Japanese cedar pollinosis.
|
